- Home
- KLRS vs SEER Comparison
KLRS vs SEER Comparison
Compare KLRS & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- SEER
- Stock Information
- Founded
- KLRS 2019
- SEER 2017
- Country
- KLRS United States
- SEER United States
- Employees
- KLRS N/A
- SEER N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- SEER Medicinal Chemicals and Botanical Products
- Sector
- KLRS Health Care
- SEER Health Care
- Exchange
- KLRS Nasdaq
- SEER Nasdaq
- Market Cap
- KLRS 129.0M
- SEER 125.3M
- IPO Year
- KLRS N/A
- SEER 2020
- Fundamental
- Price
- KLRS $2.69
- SEER $2.13
- Analyst Decision
- KLRS Buy
- SEER Hold
- Analyst Count
- KLRS 1
- SEER 1
- Target Price
- KLRS N/A
- SEER $3.00
- AVG Volume (30 Days)
- KLRS 57.0K
- SEER 93.2K
- Earning Date
- KLRS 08-15-2025
- SEER 08-06-2025
- Dividend Yield
- KLRS N/A
- SEER N/A
- EPS Growth
- KLRS N/A
- SEER N/A
- EPS
- KLRS N/A
- SEER N/A
- Revenue
- KLRS N/A
- SEER $15,309,000.00
- Revenue This Year
- KLRS N/A
- SEER $27.05
- Revenue Next Year
- KLRS N/A
- SEER $28.33
- P/E Ratio
- KLRS N/A
- SEER N/A
- Revenue Growth
- KLRS N/A
- SEER N/A
- 52 Week Low
- KLRS $2.28
- SEER $1.59
- 52 Week High
- KLRS $24.15
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- SEER 49.05
- Support Level
- KLRS N/A
- SEER $2.12
- Resistance Level
- KLRS N/A
- SEER $2.25
- Average True Range (ATR)
- KLRS 0.00
- SEER 0.07
- MACD
- KLRS 0.00
- SEER -0.00
- Stochastic Oscillator
- KLRS 0.00
- SEER 31.43
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.